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Purpose: Radiotherapy is an effective tool for cancer control, but side effects on normal 
tissue limit its therapeutic effectiveness. Thus, the search for agents that may allow the use 
of high doses of radiation but exerting a differential protection to healthy tissue is of current 
concern. Resveratrol (3, 5, 4'-trihydroxy-trans-stilbene) (RSV) is a polyphenol with 
pleiotropic benefits for health due to its antioxidant and anti-inflammatory properties. Recent 
findings suggest that RSV could be promising in the fight against cancer since it inhibits the 
growth of tumor cells and optimizes radiotherapy. However, evidence in rodents and human 
beings is inconsistent. The aim of this study was to evaluate the radiomodulatory capacity of 
RSV on human lymphocytes.  
Materials and methods: To study these properties of RSV, human peripheral blood 
lymphocytes from 20 healthy women undergoing in vivo RSV treatment with 50 mg/day 
doses were irradiated. The genotoxic damage was assessed by the comet assay, also called 
single cell gel electrophoresis (it makes it possible to measure the extent of the DNA 
migration from individual cells, detecting the genomic damage present in each cell). 
Results: No differences were observed in basal clastogenic damage among samples without 
irradiation. There was only a slight radiation-induced clastogenic damage. The Damage 
Index (DI) value had a statistically significant increase in the exposed groups in comparison 
with the control groups (p<0.0001), but a statistically significant decrease of the DI value 
was observed in samples irradiated after treatment with RSV compared to pre-treatment 
samples (p<0.0001). 
Conclusion: The RSV used as a dietary supplement had radioprotective properties, without 
exerting cytotoxic effect. The potential utility of RSV to optimize the radiotherapeutic ratio 
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1. Introduction 
Radiotherapy is a common therapeutic modality in modern medicine based on the use 
of ionizing radiation for cancer treatment (United Nations Scientific Committee on the 
Effects of Atomic Radiation 2008; Barnett et al. 2015). Although radiation is effective for 
disease control, side effects such as damage in normal tissues surrounding the tumor limit its 
therapeutic benefits (West and Barnett 2011; Raabe et al. 2012). Recent advances have 
focused on achieving an optimal balance between tumoricidal efficacy and acceptable toxic 
effects. Usually, radiotherapy is performed using many relatively small fractions of radiation, 
but currently, there is a push to increase overall total dose and to increase in fraction size 
mostly taking advantage of more accurate delivery thus avoiding or giving less dose to the 
surrounding normal tissue. Therefore, there is interest in protecting the normal tissue, so 
research is centered in finding agents that exerts a differential protection to healthy tissue. 
Since cellular damage induced by electromagnetic radiation is mainly attributed to the 
harmful effect of free radicals (Zhang et al. 2013; Li et al. 2014; Koohian et al. 2017), 
substances that could eliminate them are particularly attractive as radio-modulators. A large 
number of natural and synthetic compounds such as antioxidants, cytoprotective agents and 
vitamins have been extensively studied in in vitro and in vivo models (Brisdelli et al. 2009). 
Unfortunately, some radioprotectors are toxic at the doses required for this end, and many 
synthetic agents have not been used in clinical applications yet. In addition, the search for 
new agents for cancer prevention and treatment has been strengthened in recent years due to 
the progressive increase of the disease as a result of both life style changes and increased 
longevity (GLOBOCAN 2018). Natural products have always been an important source of 
these new agents; thus, numerous studies have focused on biologically active substances of 











Resveratrol (3,5,4'-trihydroxy-trans-stilbene) (RSV) is a polyphenol commonly 
obtained from grapes and their derivatives and also synthesized by several plant species in 
response to biotic and abiotic stress. The compound has shown pleiotropic benefits for health, 
particularly because of its antioxidant, anti-inflammatory, anti-aging, cardioprotective and 
neuroprotective activities (Brisdelli et al. 2009; Shukla and Singh 2011; Carter et al. 2014; 
Poulsen et al. 2015). Considering that some of these properties are supposed to counteract 
both the carcinogenic process and the side effects of the radiant protocols, much of the 
current research on RSV is concerned with its possible application in oncology as a 
therapeutic and/or chemopreventive agent (Singh CK et al. 2015). In this sense, recent 
findings from our laboratory and other research groups suggest that RSV could be promising 
in the fight against cancer as well as in the improvement of radiation therapy (Kundu and 
Surh 2008; Brisdelli et al. 2009; Carter et al. 2014). As a polyphenolic compound, RSV 
removes hydroxyl and superoxide radicals and promotes the activity of antioxidant enzymes 
such as superoxide dismutase and catalase. Their reduction prevents DNA damage, which 
could be useful in oncological radiotherapy to avoid normal tissue damage (Brisdelli et al. 
2009).  
On the other hand, recent work has remarkably advanced our understanding of the 
molecular mechanisms underlying RSV anticancer properties. For instance, it has been 
shown to inhibit or retard the growth of tumor cells in vitro and tumors implanted in vivo 
(Brisdelli et al. 2009; Banegas et al. 2018). However, although the data obtained from cell 
cultures are promising, evidence in rodents and human beings is scant and inconsistent. 
Contradictory results may be due to the route of administration and the dose or animal 
species used, among other factors. Thus, the transfer of RSV to the clinical area is still far 
from real considering the challenges to be addressed, namely, from metabolic issues to the 











According to the above mentioned and previous results obtained by our research group 
(Banegas et al. 2018), the aim of this study was to evaluate the radiomodulatory capacity of 
RSV in 4 Gy-irradiated human peripheral blood lymphocytes from healthy women 
undergoing in vivo RSV treatment. 
 
2. Materials and methods 
 
2.1. Chemicals 
Low-melting-point agarose (LMA), normal-melting point agarose (NMA), NaCl, Na-
EDTA, Tris, NaOH, Triton X-100, ethanol, EDTA and dimethyl sulfoxide (DMSO) were 
obtained from Invitrogen (California, USA), Biopack (Buenos Aires, Argentina) and Carlo 
Erba Reagents (Barcelona, Spain). Resveratrol capsules were purchased from N.S. Products 
S.R.L. (Buenos Aires, Argentina), RPMI 1640 Medium from Gibco (California, USA) and 
Sybr green from Sigma-Aldrich (Missouri, USA) 
 
2.2. Study design 
The experimental group was composed of healthy, non-smoking female volunteers with 
similar nutritional conditions. Participants received one capsule of 50 mg RSV daily under 
fasting conditions for 15 consecutive days. A sample of about 5 mL peripheral blood was 
drawn in labelled tubes containing lithium heparin as anticoagulant (Monovettes®; Sarstedt, 
Nümbrecht, Germany) at the beginning and end of this treatment. Immediately afterwards, 
two aliquots of blood (1 mL each) were separated and centrifuged for 5 min at 1000 rpm at 
20 °C. Plasma was removed and replaced for an equal volume of RPMI, and the pellets were 
resuspended. One aliquot was irradiated with 4 Gy and the other was used as experimental 











The study was performed in accordance with the core principles of the Good Clinical 
Practice Guidelines (Vijayananthan and Nawawi 2008) and following the principles of the 
Declaration of Helsinki. All donors were properly informed of the purposes of this study and 
gave their written informed consent. 
A total of 20 healthy female subjects (age range, 20-30 years) were recruited. General 
characteristics of the study sample are presented in Table 1. Eligibility criteria met the 
following requirements: normal physical examination, vital signs and laboratory screening 
results within normal ranges, willingness to abstain from specific foodstuff and beverages, 
ability to understand the full nature and purpose of the study, non-smoking, non-pregnant and 
non-lactating women (Sergides et al. 2016). Exclusion criteria included history of 
hypersensitivity to the test substance and the inactive ingredients, hospitalization for any 
reason or blood donation (≥ 450 ml) within 12 weeks prior to the initiation of the study, 
intake of any drugs within 4 weeks prior to or during the study, history or presence of any 
relevant medical condition, history of drug or alcohol abuse, and subjects that were 
vegetarian or followed a particular diet. 
From three days prior to the study and up to 24 h after the last RSV dose, volunteers 
maintained a strict diet, avoiding the consumption of foods or beverages with a high RSV 
content such as red/black fruit, kiwi fruit, red/black grapes, peanuts, nuts and red wine. The 
diet was controlled during the entire treatment period. Each RSV tablet was administered 
orally with 200 ml water early in the morning on an empty stomach. 
 
2.3. Irradiation procedure  
Cell irradiation was performed with a VarianClinac® 6MV linear accelerator (Varian 
Medical Systems, Palo Alto, California, USA). The dose rate was calculated using isocentric 











in an immobilized rack inside an acrylic phantom with water, whose density was equivalent 
to soft tissue and whose depth was greater than the buildup zone. This system was placed on 
a “tennis racket” support panel of the accelerator and irradiated from the bottom with 4 Gy 
isocentric photon beams using a 10-15 X field size. The deviation of the absorbed dose was 
less than 5%, which was compatible with the therapeutic objective. The samples were 
irradiated at room temperature, but immediately after that they were put on ice. Despite for 
conventional radiotherapy treatments the exposure is usually given on 2 Gray fractions once 
per day five days per week, previous results obtained in our laboratory showed that 4 Gy was 
optimal in relation to the sensitivity of the technique used (Olive 2009; Banegas et al. 2018).  
 
2.4. Comet assay 
Cytomolecular genotoxic damage in peripheral blood was assessed immediately after 
each radiation treatment with the alkaline version of the comet assay according to Singh NP 
et al. (1988) with slight modifications. Microscopic slides were coated with NMA and kept at 
room temperature for agarose gel solidification. Twenty microliters of treated cells were 
mixed with 160 µL LMA in phosphate-buffered saline; 90 µl of the mixture were layered on 
each slide, spread out with a cover slip and kept at 4 °C for 10 min. After solidification, 
coverslips were removed and slides were immersed in cold lysing solution (2.5 M NaCl, 100 
mM Na2EDTA, 10 mM Tris, pH 10); then, 1% Triton X-100 and 10% DMSO were added 
just before use. After lysis, the slides were placed in a horizontal gel electrophoresis tank 
filled with alkaline buffer (300 mM NaOH and 1 mM EDTA, pH 13) for 20 min at 4 °C to 
allow DNA unwinding and the expression of alkali-labile damage. Electrophoresis was 
performed for 25 min at 250 mA and 25 V. After electrophoresis, the slides were washed 













2.5. Microscopic analysis and scoring 
Slides were scored under blind code. They were stained with 20 µl Sybr green (1/2000 
dilution) just before the microscopic analysis. A total of 100 randomly captured cells per 
slide were visually analyzed under a fluorescence microscope with excitation filters of 515-
560 ηm (Olympus BX40®, Tokyo, Japan) at 400 magnification. Each experimental point was 
evaluated in duplicate. Thus, total cell observations included 800 cells per volunteer (200 
cells per condition). The degree of damage was determined visually according to Collins et 
al. (1995) (Kumaravel et al. 2009). Each cell was classified into 5 classes, from class 0 (no 
DNA migration) to class 4 (maximum DNA migration). Genetic damage was measured with 
the damage index (DI), calculated with the formula DI = [ (1×n1) + (2× n2) + (3× n3) + (4× 
n4)] / (n0 + n1 + n2 + n3 + n4) x 100, where n indicates the number of cells in each class. 
Damage class (DC) was calculated as the sum of cells with 0 (null), 1 and 2 (slight), and 3 
and 4 (severe) damage.  
 
2.6. Statistical analysis 
Data were analyzed using Student´s t-test and Chi-square test. Results are expressed as 
means ± SEM. 
 
3. Results 
All volunteers completed the study. The demographic characteristics of participants are 
presented in Table 1 (mean age, 25.39 ± 2.44 years [range, 22 - 30 years]; mean weight, 
60.43 ± 6.018 kg [range, 49.2–76.0 kg); mean height, 1.62 ± 0.06 m [range, 1.48–1.76 m]; 
mean Body Mass Index kg/m
2











Mean frequency of comet classes for each experimental point is shown in Table 2. 
Comet classes 3 and 4 were observed more frequently in the irradiated than in the control 
groups, while comet class 0 was observed more frequently in controls. [Table 2 near here] 
Figure 1A shows DC of blood samples taken before and after daily RSV administration 
for 15 days. No significant differences were observed in basal clastogenic damage among 
control, pre- and post-treatment samples without irradiation, suggesting that both RSV and its 
metabolites did not exert a genotoxic effect at the dose administered. Despite the absence of 
unwanted side effects in volunteers, our results failed to verify the antioxidant capacity of 
RSV. Radiation-induced clastogenic damage comparing irradiated cells (4 Gy) before and 
after treatment, was slight and mostly corresponded to comet grades 2 and 3 (Figure 1A). 
This tendency was repeated in all volunteers. Figure 1B shows the DI of blood samples. 
While the lowest DI value was observed in the control groups (not irradiated), both before 
(mean DI 24,72 ± 6,42) and after (mean DI 19,07 ± 4,05) treatment with RSV, this parameter 
had a significant increase in the exposed groups (p<0.0001). An important DI decrease 
(p<0.0001) was observed in samples irradiated after treatment with RSV (mean DI 120,52 ± 
9,22) compared to pre-treatment samples (mean DI 171,91 ± 6,44), it was noted that the DI 
increased with the irradiation and decreased with the RSV treatment. [Figure 1 near here] 
 
4. Discussion 
Currently, radiotherapy is the cornerstone of cancer treatment considering that it is a 
targeted and non-invasive therapy, with good organ preservation. However, its side effects on 
normal tissue limit its use, making it necessary to find agents to mitigate them (Citrin et al. 
2010). Although radiotoxicity would be related to immediate and widespread oxidative 
damage to the genetic material of irradiated cells, new paradigms propose broader 











general, cell damage has been attributed to the increase in reactive oxygen species that induce 
functional alterations in lipids, proteins and nucleic acids (Zhang et al. 2013; Li et al. 2014; 
Dobrzynska et al. 2016). Thus, molecules with free radical scavenging properties are 
particularly promising as radio protectors, and their clinical use has been investigated during 
the last years. Since these compounds frequently have side effects and toxicity (Sebastia et al. 
2013; Li et al. 2014), the focus is now being placed on natural compounds with lower toxicity 
than the synthetic substances and with most favorable administration routes (Sebastia et al. 
2013). Among them, RSV has been highly promoted both as antioxidant and anticancer 
(Shukla and Singh 2011; Zhang et al. 2013). Such dual mechanism of action constitutes the 
fundamental basis of a radio-protective substance, i.e., protective for normal cells and toxic 
for tumor cells (Fabre et al. 2011; Sebastia et al. 2014).   
Taking into account the tissue analyzed in this study (human peripheral blood), an 
important aspect to consider is that the side effects of radiotherapy vary depending on the 
area treated, the general condition of the patient and the type and dose of radiation used. 
Treatment over large areas of the body, such as bones that contain a main part of the bone 
marrow, for example pelvis, legs, thorax, or abdomen, may lead to drop of the white and red 
blood cell count (American Cancer Society 2019; American Society of Clinical Oncology 
2017). In relation, it is suggested that special treatments, such as Total Body Irradiation, 
induce significant leukopenia. It has also been observed a reduction in the number of 
circulating leukocytes and lymphocytes in cervical and endometrium radiotherapy (van Meir 
et al. 2017). In this way and in agreement with Yi et al. (2019), there is a need to consider 
agents, such as resveratrol, that provide protection against hematopoietic injury induced by 
irradiation. On the other hand, currently relevant protocols like hypofractionated 
radiotherapy, induce damage on infiltrating lymphocytes (Arnold et al. 2018), and could also 











Most studies related to the possible application of RSV in oncological therapy have been 
carried out in in vitro models. Results of in vivo treatments are scarce, and evidence for their 
clinical use in human beings is still inconsistent (Carter et al. 2014) even more when 
administered along with other therapies. Thus, we evaluated the effectiveness of RSV against 
radiation-induced genetic damage after in vivo treatments and studied its genotoxicity in 
human lymphocytes to optimize the most widely used oncological treatment these days.  
Previous studies from our group (Banegas et al. 2018) and other authors (Zhang et al. 
2013; Sebastia et al. 2014; Meng et al. 2016) indicate that the chemo-protective effect of 
RSV depends on the dose administered and the synergistic interaction with other drugs or 
cytotoxic factors. Accordingly, the dose recommended as a dietary supplement (50 mg/day) 
and that showed results in mice (Koohian et al. 2017) was chosen, considering that doses of 2 
mg/kg/day in human beings would exercise radioprotection and that there was no toxicity 
from 25 mg to 5 g/day. In this sense, our results could experimentally guarantee that 
treatment of young and healthy women with such dose had good systemic tolerance and no 
stomach discomfort, dizziness, fatigue, headache or cutaneous reactions. 
Genotoxic damage and the radiomodulatory potential of RSV were analyzed with the 
comet assay, taking into account its high sensitivity to detect and quantify DNA damage 
induced by several agents and by ionizing radiation. This test allowed the analysis of DNA 
strand breaks induced by x-irradiation in the presence or absence of RSV. The entero-hepatic 
recirculation of the compound enabled its slow elimination while allowing prolonged effects 
(Delmas et al. 2006), being it therefore plausible to detect it in the post-treatment times 
evaluated. 
The fact that no significant differences were observed in cytomolecular DI before and 
after in vivo treatment with RSV suggests that RSV and its secondary metabolites did not 











Thus, the interference of RSV with topoisomerases and increased DNA damage attributed to 
RSV (Sebastia et al. 2013) could not be demonstrated. On the other hand, RSV 
radioprotective effect against ionizing radiation-induced genotoxicity could be seen. In our 
study, pretreatment with RSV decreased DNA strand breaks in irradiated human 
lymphocytes, which agrees with Carsten et al. (2008), who endorsed that oral RSV 
administration to mice acted as a generalized radioprotector, decreasing the frequency of 
chromosomal aberrations induced by radiation in the same cells. Our observation that 
treatment with RSV decreased DI by 29.41% in irradiated lymphocytes clearly indicated that 
RSV prevented radio-induced DNA damage. This is also in agreement with Koohian et al. 
(2017), who found that RSV offered the best protection with low toxicity against 2 Gy 
irradiation in mice evaluating the effects by the comet assay.  
Taking the genotoxicity and radiomodulation analyses of this work together, in vitro 
evidence also showed that although trans-resveratrol decreased the damage in blood 
lymphocytes exposed to 2 Gy X-rays, few chromosomal aberrations were found when these 
cells were treated with RSV without being exposed to radiation (Sebastia et al. 2013; Sebastia 
et al. 2014; Dobrzynska et al. 2016). On the topic of the mechanisms of action, RSV is a 
hydrophobic compound able to cross cell membranes and eliminate radio-induced free 
radicals that are close to the DNA double helix and alter its structure (Koohian et al. 2017). 
Thus, RSV is able not only to scavenge these free radicals but also to maintain and restore the 
levels of intra-cellular antioxidants (Carsten et al. 2008; Sebastia et al. 2013; Zhang et al. 
2013). At molecular level, RSV decreased the effects of radiation at least partly based on 
Sirt1 expression and activity (Zhang et al. 2013; Li et al. 2014). This protein plays an 
important role in oxidative stress, cell proliferation and genomic stability, among other 
biological processes. An increase in Sirt1 mRNA and in protein activity has been 











Ultimately, it should be noted that RSV systemic impact would also be effective in 
relation to the holistic effect of irradiations, since it exhibits anti-inflammatory activity 
through the modulation of enzymes and mediators of inflammation (Kundu and Surh 2008; 
Udenigwe et al. 2008), and also enhances the immune response against cancer (Soldati et al. 
2018), both central elements of the response to radiant treatment.  
 
5. Conclusions 
Our results suggest that RSV could be a successful radiomodulator to protect human 
lymphocytes from the harmful effects of irradiation. Daily doses of 50 mg did not show 
genotoxic risk, nor did they present adverse effects that may generate controversies among 
doctors or patient concern. Administration of RSV could help to protect against genomic 
instability and eventual radio-induced carcinogenesis, as well as against the side effects of 
radiant treatments. In this way, radiotherapy, as well as other oncological treatments, 
diseases, certain medications and poor nutrition, can affect white blood cells, weakening the 
immune system. This deficit of white blood cells that sensitizes the individual to an infection 
could be counteracted by the supply of appropriate substances such as RSV. The good 
pharmacological availability and affordable cost position RSV as a good candidate to 
optimize the radiotherapeutic quotient promoting the elimination of cancer cells subject to 
radiotherapy and decreasing chronic oxidative stress and inflammation responsible for the 
side effects of this treatment. 
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Figure 1. Radiation-induced genotoxic effect evaluated in human peripheral blood lymphocytes 
pre and post-treatment with RSV. Panel A: Clastogenic damage class for each of the analyzed 
points, expressed as mean ± SEM of 20 samples in duplicate. Panel B: Damage index for each 
treatment performed, expressed as mean ± SEM of 20 samples in duplicate. **** p <0.0001 
control vs 4Gy, pre and post treatment. #### p <0.0001 pre vs. post treatment irradiated with 4 












Table 1. Demographic characteristics of the study sample.  
Volunteer Age Weight (kg) Height  
(m) 
Body Mass Index (kg/m
2
) 
1 23 64.600 1.60 25.234 
2 22 53.000 1.54 22.348 
3 24 70.000 1.64 26.026 
4 25 70.000 1.62 26.673 
5 24 61.500 1.61 23.726 
6 24 52.500 1.62 20.005 
7 22 60.000 1.55 24.974 
8 25 61.000 1.63 22.959 
9 25 61.000 1.65 22.406 
10 29 60.000 1.65 22.039 
11 24 63.000 1.60 24.609 
12 24 64.000 1.63 24.088 
13 25 60.000 1.60 23.438 
14 26 64.000 1.64 23.795 
15 30 52.000 1.64 19.334 
16 29 53.000 1.64 19.706 
17 28 63.000 1.65 23.140 
18 24 71.000 1.70 24.567 
19 27 62.000 1.76 20.015 
20 30 49.200 1.48 22.462 
Range 22 - 30 49.2 - 76.0 1.48 - 1.76 19.33 - 29.69 
Mean 25.39 60.435 1.62 22.98 















Class 0 Class 1 Class 2 Class 3 Class 4 
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM 
Pre-treatment Control 79.34 4.92 7.63 2.27 12.31 4.22 0.00 0.00 0.71 0.26 
Pre-treatment 4Gy 4.80 2.36 22.06 3.09 70.97 4.23 0.37 0.19 1.80 0.56 
Post-treatment Control 88.05 2.46 5.10 0.92 6.67 1.75 0.00 0.00 0.18 0.10 
Post-treatment 4Gy 19.00 4.83 43.29 4.25 36.60 5.03 0.02 0.03 1.09 0.58 
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